Dr. Gay is a member of the Executive Committee of the President's Leadership Council of Brigham Young University (BYU) and a member of the national Advisory Council of the Marriott Business School at BYU. He has taught economics at Harvard University where he also received a Ph.D. in Business Economics and the Harvard Business School Division of Research Scholarship.
Dr. Gay joins Board members Gary Crocker, President of Crocker Ventures, James Dresser, Chairman of the Board of Trustees of Wesleyan University and former Chief Administrative Officer at the Boston Consulting Group, Gordon Fehr, former Chairman and President of Pfizer Canada, Peter Lewis, President of Wharton Equity Partners, LLC, Walter Lovenberg, PhD, President of Lovenberg Associates and former Chief of the Section of Biochemical Pharmacology at the National Institutes of Health, Anthony Sinskey, PhD, co-Founder of Merrimack and Professor of Microbiology in the Biology Department at MIT and Robert Mulroy, President and CEO of Merrimack Pharmaceuticals.
Merrimack Pharmaceuticals, Inc., is a biotechnology company focused on
the discovery and development of novel treatments for diseases in the areas
of autoimmune disease and cancer. Its lead compound, MM-093, is currently
in clinical development to treat patients with rheumatoid arthritis or with
autoimmune uveitis. MM-093 is an investigational drug and has not been
approved by the U.S. Food and Drug Administration or any international
regulatory agency. The company's proprietary Network Biology discovery
platform, developed with the help of leading scientists from MIT and
Harvard, enables the high throughput profiling of protein networks as a
basis for improved validation, lead identification and speed in the
development of innovative, effective and safe therapeutics. Merrimack is a
privately-held company based in Cambridge, Massachusetts. For additio
|SOURCE Merrimack Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved